Blood Podcast Pembrolizumab plus AVD for classical Hodgkin lymphoma, targeting the CD40/CD40-ligand axis in Waldenström Macroglobulinemia, and CXCR4-expressing CAR-cytokine induced killer cells in AML
May 25, 2023
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8
Introduction
00:00 • 3min
The Safety and Tolerability of Pembrolysumab Therapy
02:45 • 3min
The Safety and Effectiveness of PD-1 Blockade for Hodgkin Lymphoma
05:15 • 2min
Targeting the Immune Microenvironment in Waldenstrom Macroglobulinemia
06:52 • 2min
The Role of T-Regs in Waldenstrom Macroglobulinemia
08:36 • 3min
The Role of T-Reg in the Pathogenesis of Waldenstrom Macroglobulinemia
11:12 • 4min
The Role of CXCR4 in CAR T-Cell Therapy in AML
14:44 • 2min
The Potential Benefits of Arming CD33 CAR Cytokine-Induced Killer Cells With CXCR4
16:52 • 4min